Samir D. Undevia

Medicine · Health Sciences

24h-index3.4kcitations71works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(17), Cancer therapeutics and mechanisms(16), Cancer Treatment and Pharmacology(13), PI3K/AKT/mTOR signaling in cancer(11), Vascular Tumors and Angiosarcomas(10)

Publications71 total

Data from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Supplementary Table 2 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
CCR Translation for the Article from Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
2023Open Access
CCR Translation for the Article from Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
2023Open Access
Supplementary Table 1 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Supplementary Table 3 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Data from Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
2023Open Access
Supplementary Table 2 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Supplementary Table 3 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Data from Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
2023Open Access
Supplementary Table 1 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Data from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
2023Open Access
Toxicity and Efficacy of Stereotactic Body Radiotherapy plus Nivolumab with Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors
International Journal of Radiation Oncology*Biology*Physics·2020
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
European Journal of Cancer·2019· 28 citedOpen Access
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
Cancer·2019· 76 citedOpen Access
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Annals of Oncology·2019Open Access
An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population
Journal of Racial and Ethnic Health Disparities·2016· 13 cited
3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy
European Journal of Cancer·2015· 1 cited
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
Investigational New Drugs·2015· 14 cited
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Annals of Oncology·2015· 20 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Mark J. Ratain(30), Federico Innocenti(12), Jacqueline Ramı́rez(12), Linda Janisch(10), Walter M. Stadler(8), Robert G. Maki(7), Scott M. Schuetze(7), Richard L. Schilsky(7), Larry House(7), Theodore Karrison(6), Bruce Brockstein(6), Michael L. Maitland(6), Michael B. Livingston(5), David Geary(5), Masha Kocherginsky(4), David R. D’Adamo(4), Andrew S. Kraft(4), Gary K. Schwartz(4), Kristin Moshier(4), Ezra E.W. Cohen(4)